- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Empagliflozin May Relieve Angina Symptoms and Improve Endothelial Function in ANOCA: Study

USA: An open-label pilot published in Arteriosclerosis, Thrombosis, and Vascular Biology found that empagliflozin (Jardiance), an SGLT2 inhibitor, may provide clinically meaningful symptom relief in patients with angina with nonobstructive coronary arteries (ANOCA) associated with microvascular and vasomotor dysfunction. The treatment also appeared to reverse several measures of endothelial dysfunction. These preliminary findings warrant confirmation in larger, controlled clinical trials.
- Improved angina symptoms: The Seattle Angina Questionnaire summary score increased by 14 points after 90 days of treatment (95% confidence interval, 4.2–23.9; p less than 0.001), indicating a meaningful improvement in angina-related health status.
- Reduced inflammation and oxidative stress: Empagliflozin was associated with lower levels of inflammatory cytokines, oxidative stress biomarkers, and inflammatory eEVs. Anti-inflammatory cytokines, antioxidants, and repair-associated eEVs increased during treatment.
- Improved endothelial function: Laboratory experiments showed reductions in endothelial cell death, eEV release, vascular cell adhesion molecule-1 (VCAM-1) expression, and mitochondrial reactive oxygen species following treatment.
- Effects reversed after discontinuation: In a subset of five participants, several improvements in biomarkers and endothelial cell function diminished after empagliflozin was stopped.
MSc. Biotechnology
Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

